iRadimed (NASDAQ:IRMD) CEO Sells $506,900.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $101.38, for a total transaction of $506,900.00. Following the completion of the sale, the chief executive officer owned 2,242,500 shares of the company’s stock, valued at $227,344,650. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

iRadimed Price Performance

NASDAQ IRMD opened at $99.50 on Friday. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $107.90. The stock’s 50-day moving average is $100.47 and its two-hundred day moving average is $89.49. The firm has a market cap of $1.27 billion, a P/E ratio of 56.86 and a beta of 1.12.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, equities analysts expect that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, February 23rd. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. iRadimed’s dividend payout ratio (DPR) is currently 45.71%.

Institutional Trading of iRadimed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its holdings in shares of iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after buying an additional 205,783 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of iRadimed by 37.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after acquiring an additional 55,426 shares during the period. Informed Momentum Co LLC acquired a new stake in shares of iRadimed in the fourth quarter worth $5,361,000. SG Americas Securities LLC grew its stake in shares of iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after acquiring an additional 33,072 shares during the last quarter. Finally, Invesco Ltd. increased its position in iRadimed by 473.9% during the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock worth $3,418,000 after acquiring an additional 29,010 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on IRMD shares. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Roth Mkm reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.